carbamates has been researched along with Heart Failure in 11 studies
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this analysis of electronic health record data from a large database in China, metformin as first-line monotherapy greatly reduced the risk of all-cause death, cardiovascular death, and heart failure in diabetes patients as compared with nonmetformin medications." | 8.02 | Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study. ( Chen, X; Chen, Y; He, S; Li, G; Qian, X; Shen, X; Xu, X; Zhang, B, 2021) |
| "The animal and human pharmacology of several new drugs (prazosin, trimazosin, pirbuterol, and carbazeran) useful in the treatment of congestive heart failure (CHF) is delineated in relation to the pharmacology of other agents employed for CHF management." | 6.15 | Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure. ( Baird, JR; Blackburn, KJ; Cambridge, D; Constantine, JW; Ghaly, MS; Hayden, ML; McIlhenny, HM; Moore, PF; Olukotun, AY; Pullman, LG; Salsburg, DS; Saxton, CA; Shevde, S; Taylor, CR, 1981) |
| "In this analysis of electronic health record data from a large database in China, metformin as first-line monotherapy greatly reduced the risk of all-cause death, cardiovascular death, and heart failure in diabetes patients as compared with nonmetformin medications." | 4.02 | Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study. ( Chen, X; Chen, Y; He, S; Li, G; Qian, X; Shen, X; Xu, X; Zhang, B, 2021) |
| "Cardiomyocyte BRAFV600E induced cardiac hypertrophy within 10 d, resulting in increased ejection fraction and fractional shortening over 6 weeks." | 1.72 | Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo. ( Alharbi, HO; Barton, PJ; Chothani, SP; Clerk, A; Cook, SA; Cooper, STE; Cull, JJ; Felkin, LE; Fuller, SJ; Glennon, PE; Hardyman, MA; Leonard, SJ; Markou, T; McTiernan, CF; Meijles, DN; Rackham, OJL; Rojas, M; Sembrat, JC; Shaw, SW; Sheppard, MN; Sugden, PH; Vanezis, K, 2022) |
| "Cardiovascular adverse events (CVAEs) associated with BRAF inhibitors alone versus combination BRAF/MEK inhibitors are not fully understood." | 1.62 | Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries. ( Al-Kindi, S; Barnholtz-Sloan, JS; de Lima, M; Dowlati, A; Fradley, MG; Guha, A; Gutierrez, JM; Jain, C; Jain, P; Lenihan, D; Oliveira, GH, 2021) |
| "BPMC also induced cerebral hemorrhages and blood erythrocyte reduction in a dose-dependent manner." | 1.51 | Fenobucarb induces heart failure and cerebral hemorrhage in zebrafish. ( Li, CQ; Li, P; Wu, YY; Xia, B; Yang, H; Zhu, XY, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (36.36) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Clerk, A | 1 |
| Meijles, DN | 1 |
| Hardyman, MA | 1 |
| Fuller, SJ | 1 |
| Chothani, SP | 1 |
| Cull, JJ | 1 |
| Cooper, STE | 1 |
| Alharbi, HO | 1 |
| Vanezis, K | 1 |
| Felkin, LE | 1 |
| Markou, T | 1 |
| Leonard, SJ | 1 |
| Shaw, SW | 1 |
| Rackham, OJL | 1 |
| Cook, SA | 1 |
| Glennon, PE | 1 |
| Sheppard, MN | 1 |
| Sembrat, JC | 1 |
| Rojas, M | 1 |
| McTiernan, CF | 1 |
| Barton, PJ | 1 |
| Sugden, PH | 1 |
| Guha, A | 1 |
| Jain, P | 1 |
| Fradley, MG | 1 |
| Lenihan, D | 1 |
| Gutierrez, JM | 1 |
| Jain, C | 1 |
| de Lima, M | 1 |
| Barnholtz-Sloan, JS | 1 |
| Oliveira, GH | 1 |
| Dowlati, A | 1 |
| Al-Kindi, S | 1 |
| He, S | 1 |
| Qian, X | 1 |
| Chen, Y | 1 |
| Shen, X | 1 |
| Zhang, B | 1 |
| Chen, X | 1 |
| Xu, X | 1 |
| Li, G | 1 |
| Gottlieb, RL | 1 |
| Sam, T | 1 |
| Wada, SY | 1 |
| Trotter, JF | 1 |
| Asrani, SK | 1 |
| Lima, B | 1 |
| Joseph, SM | 1 |
| Gonzalez-Stawinski, GV | 1 |
| Hall, SA | 1 |
| Zhu, XY | 1 |
| Xia, B | 1 |
| Wu, YY | 1 |
| Yang, H | 1 |
| Li, CQ | 1 |
| Li, P | 1 |
| McLean, RC | 1 |
| Reese, PP | 1 |
| Acker, M | 1 |
| Atluri, P | 1 |
| Bermudez, C | 1 |
| Goldberg, LR | 1 |
| Abt, PL | 1 |
| Blumberg, EA | 1 |
| Van Deerlin, VM | 1 |
| Reddy, KR | 1 |
| Bloom, RD | 1 |
| Hasz, R | 1 |
| Suplee, L | 1 |
| Sicilia, A | 1 |
| Woodards, A | 1 |
| Zahid, MN | 1 |
| Bar, KJ | 1 |
| Porrett, P | 1 |
| Levine, MH | 1 |
| Hornsby, N | 1 |
| Gentile, C | 1 |
| Smith, J | 1 |
| Goldberg, DS | 1 |
| Lee, YC | 1 |
| Chang, CH | 1 |
| Dong, YH | 1 |
| Lin, JW | 1 |
| Wu, LC | 1 |
| Hwang, JS | 1 |
| Chuang, LM | 1 |
| el Allaf, D | 1 |
| D'Orio, V | 1 |
| Carlier, J | 1 |
| Hillis, WS | 1 |
| Been, M | 1 |
| Taylor, CR | 1 |
| Baird, JR | 1 |
| Blackburn, KJ | 1 |
| Cambridge, D | 1 |
| Constantine, JW | 1 |
| Ghaly, MS | 1 |
| Hayden, ML | 1 |
| McIlhenny, HM | 1 |
| Moore, PF | 1 |
| Olukotun, AY | 1 |
| Pullman, LG | 1 |
| Salsburg, DS | 1 |
| Saxton, CA | 1 |
| Shevde, S | 1 |
| Müntzing, J | 1 |
| Shukla, SK | 1 |
| Chu, TM | 1 |
| Mittelman, A | 1 |
| Murphy, GP | 1 |
3 reviews available for carbamates and Heart Failure
| Article | Year |
|---|---|
The new inotropic phosphodiesterase inhibitors.
Topics: Aminopyridines; Amrinone; Calcium; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Enoximone; | 1984 |
Phosphodiesterase inhibitors: haemodynamic effects related to the treatment of cardiac failure.
Topics: Aminophylline; Animals; Carbamates; Heart Failure; Heart Rate; Hemodynamics; Humans; Myocardial Cont | 1982 |
Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure.
Topics: Animals; Asthma; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Clinical Trials as Topic; Dr | 1981 |
2 trials available for carbamates and Heart Failure
| Article | Year |
|---|---|
Transplanting hepatitis C virus-infected hearts into uninfected recipients: A single-arm trial.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Female; Genotype; Gra | 2019 |
Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure.
Topics: Animals; Asthma; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Clinical Trials as Topic; Dr | 1981 |
7 other studies available for carbamates and Heart Failure
| Article | Year |
|---|---|
Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo.
Topics: Animals; Carbamates; Cardiomegaly; Cell Size; Cells, Cultured; Dimerization; Gene Knock-In Technique | 2022 |
Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study.
Topics: Aged; Benzamides; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Di | 2021 |
Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse.
Topics: Adult; Antiviral Agents; Carbamates; Drug Combinations; Female; Heart Failure; Heart Transplantation | 2017 |
Fenobucarb induces heart failure and cerebral hemorrhage in zebrafish.
Topics: Animals; Apoptosis; Carbamates; Cardiac Output; Caspases; Cerebral Hemorrhage; Dilatation, Pathologi | 2019 |
Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study.
Topics: Acarbose; Administration, Oral; Age Factors; Aged; Carbamates; Cohort Studies; Confidence Intervals; | 2017 |
Pharmacoclinical study of oral estramustine phosphate (Estracyt) in advanced carcinoma of the prostate.
Topics: Acid Phosphatase; Administration, Oral; Antineoplastic Agents; Carbamates; Carcinoembryonic Antigen; | 1974 |